-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Gx+EuANA/sYSiXMvaw6stStm9vFJZRfTvvTO6tabmoSvGU9ghOZ180hbRNfNp712
 jVOZtvh/qu0UNzyyxwdLog==

<SEC-DOCUMENT>0000842023-07-000010.txt : 20070228
<SEC-HEADER>0000842023-07-000010.hdr.sgml : 20070228
<ACCEPTANCE-DATETIME>20070227183125
ACCESSION NUMBER:		0000842023-07-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070212
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070228
DATE AS OF CHANGE:		20070227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		07654673

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8502.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): February 12, 2007

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 5.02  Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers

Effective February 12, 2007, Dr. Karen A. Holbrook was elected to the Board of
Directors of Techne Corporation (the "Company") and to the Nominations and
governance Committee of the Board.  In connection with her service on the
Company's Board and the Nominations and Governance committee, Dr. Holbrook will
receive annual cash compensation and stock options pursuant to the Company's
director compensation policy.

Dr. Holbrook was not named as director pursuant to any arrangement or
understanding with any third person.  There is not currently, nor has there
been in the past, any transactions with the Company or any of its subsidiaries
or affiliates in which Dr. Holbrook has or had a direct or an indirect material
interest.

On February 12, 2007, the Company issued a press release announcing the
election of Dr. Holbrook to the Company's Board of Directors.  The press
release is attached as Exhibit 99.1 and is incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

          99.1 Press Release dated February 12, 2007.







                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: February 13, 2007               TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated February 12, 2007.


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>holbrookrelease.txt
<DESCRIPTION>PRESS RELEASE
<TEXT>
TECHNE CORPORATION ANNOUNCES THAT DR. KAREN A. HOLBROOK HAS ACCEPTED A SEAT
ON TECHNE'S BOARD

Minneapolis/February 12, 2007/--Techne Corporation (NASDAQ: TECH) today
announced that Dr. Karen A. Holbrook has accepted a Director position on
Techne's Board of Directors.  Dr. Holbrook's initial term will begin
immediately and run through October 25, 2007.  Techne's shareholders reelect
all Directors on an annual basis.

Dr. Holbrook has been the president of The Ohio State University since
October 1, 2002.   Under her direction, the University has realized its
vision of being one of the top-ranked research and teaching universities in
the country.  Ohio State's sponsored research funding is more than $650
million and it now ranks eighth among public universities in research
expenditures.   She will be resigning this position in June of 2007.
Dr. Holbrook came to Ohio State from The University of Georgia, where she
served as senior vice president for academic affairs and provost, as well as
professor of cell biology and adjunct professor of anatomy and cell biology
and medicine at the Medical College of Georgia.

Before that, Dr. Holbrook served at the University of Florida at Gainesville
as vice president for research and dean of the Graduate School, as well as
professor of anatomy and cell biology and medicine (dermatology).  She spent
the majority of her academic career as a professor of biological structure
and medicine at the University of Washington School of Medicine, where she
gained a national reputation for her expertise in human fetal skin
development and genetic skin disease and was a National Institutes of Health
(NIH) Merit awardee.  She also served as associate dean for scientific
affairs.

Dr. Holbrook has served on the Huntington Bancshares, Inc. (NASDAQ: HBAN)
Board of Directors since 2004.  In January 2007, she was appointed as a
member of the Advisory Committee to the Director of the NIH.  Dr. Holbrook
also serves on several non-profit boards, such as the American Association
for the Advancement of Science and the Association of American Medical
Colleges, among many others.

Dr. Holbrook earned her B.S. and M.S. in zoology from the University of
Wisconsin-Madison. After teaching biology at Ripon College, she earned a
Ph.D. in biological structure from the University of Washington School of
Medicine where she pursued postdoctoral training in the Department of
Medicine, Division of Dermatology.

Mr. Thomas E. Oland, TECHNE's Chairman and CEO, said "I am extremely pleased
with Dr. Holbrook's decision to accept a position on Techne's Board.  We are
very fortunate to have a person of her caliber on our Board.  I am very
confident that she will make a significant contribution to our future
success."


Forward Looking Statements:
This press release may contain forward-looking statements within the meaning
of the Private Litigation Reform Act. Forward-looking statements involve
risks and uncertainties that may affect the actual results of operations.
The following important factors, among others, have affected and, in the
future, could affect the Company's actual results: the introduction and
acceptance of new biotechnology and hematology products, the levels and
particular directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products and
related price competition, the retention of hematology OEM (private label)
and proficiency survey business, the impact of currency exchange rate
fluctuations, and the costs and results of research and product development
efforts of the Company and of companies in which the Company has invested or
with which it has formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.
            **********************************************
Techne Corporation has two operating subsidiaries: Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
Fortron Bio Science, Inc. (Fortron), located in Minneapolis, and BiosPacific,
Inc. (BiosPacific), located in Emeryville, California.  Fortron develops and
manufactures antibodies and BiosPacific is a worldwide supplier of biologics
to manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
R&D Europe is a distributor of biotechnology products.

Contact:   Greg Melsen, Chief Financial Officer
           Kathy Backes, Controller
        (612) 379-8854





</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
